hydroxychloroquine plus macrolides - versus control - for COVID-19 pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.72 [0.22, 2.41]< 10%2 studies (2/-)70.0 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.99 [0.57, 1.72]< 10%1 study (1/-)51.4 %some concernnot evaluable moderateimportant-
PCR-negative conversion 0.84 [0.41, 1.72]> 10%1 study (1/-)32.0 %NAnot evaluable important-
PCR-negative conversion (14-day) 0.55 [0.32, 0.94]> 10%1 study (1/-)1.4 %NAnot evaluable important-
PCR-negative conversion (7-day) 0.84 [0.41, 1.72]> 10%1 study (1/-)32.0 %NAnot evaluable important-

safety endpoints 00

arrhythmia 2.24 [0.23, 21.69]< 10%1 study (1/-)24.5 %some concernnot evaluable moderatenon important-
long QT 9.79 [1.27, 75.50]< 10%1 study (1/-)1.5 %some concernnot evaluable moderatenon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.